Voyager Therapeutics (VYGR) Change in Account Payables (2014 - 2026)

Voyager Therapeutics has reported Change in Account Payables for 13 years, with the latest figure at -$2.3 million in Q1 2026.

• Quarterly Change in Account Payables fell 68.14% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89000.0 (up 101.8% YoY) and the FY2025 annual result came in at $1.0 million, down 57.48% from the prior year.
• Change in Account Payables declined to -$2.3 million in Q1 2026 per VYGR's latest filing, from $2.9 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $6.0 million in Q1 2024 and troughed at -$5.0 million in Q2 2024.
• A 5-year average of $126411.8 and a median of $312000.0 in 2025 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables jumped 6927.78% in 2022, then plunged 11427.78% in 2023.
• Over 5 years, Change in Account Payables stood at $1.2 million in 2022, then plunged by 235.56% to -$1.7 million in 2023, then soared by 150.18% to $836000.0 in 2024, then surged by 246.53% to $2.9 million in 2025, then sank by 179.05% to -$2.3 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$2.3 million, $2.9 million, and $312000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.